The hypoxic cell radiosensitizer misonidazole (MISO) has recently been shown to sensitize mammalian cells and tissues to the effects of a wide variety of anticancer drugs both in vitro (Stratford et al., 1980; Roizin-Towle & Hall, 1981) and in vivo (e.g., Rose et al., 1980; Mulcahy et al., 1981; Martin et al., 1981; Twentyman, 1981) . In general, in vivo studies conducted in experimental animals with DNA cross-linking agents, such as melphalan (MEL) and cyclophosphamide, have been encouraging in thfat normal tissue toxicity is usually less markedly enhanced than is the tumour response, as indicated by the delay of tumour regrowth or decreased tumour cell survival assayed in vitro. MISO enhancement ratios are usually between 1.2-3.1 for tumour response and between 1.2-1.9 for normal tissue toxicity, such as myelosuppression or low white blood cell count (Fowler, 1982) . Phase I clinical studies of MISO in combination with DNA cross-linking agents are currently in progress (Rimondi et al., 1982; Klein et al., 1982) .
Several possible processes have been implicated in the mechanism of chemosensitization. These include: alterations in pharmacokinetics and metabolism (Stephens et al., 1981; Tannock, 1980; Clutterbuck et al., 1982) , selective toxicity towards hypoxic or non-cycling cells (Sutherland, 1974) , the generation and fixation of free-radical intermediates (Clement et al., 1980) , inhibition of the repair of potentially lethal damage (PLD) (Law et al., 1981; Martin et al., 1981; Siemann & Mulcahy, 1982) , or reduced levels of intracellular sulphydryl-containing compounds such as glutathione (GSH) (Taylor et al., 1982a; Roizin-Towle et al., 1982) which are involved in detoxification of electrophilic drugs such as MEL and are also free-radical scavengers. Although hypoxia is a prerequisite for in vitro sensitization (Stratford et al., 1980; Roizin-Towle & Hall, 1981) , its exact significance in terms of normal tissue versus tumour toxicity in vivo is unclear (Tannock, 1980; Law et al., 1981) .
In this paper, it has been our intention to observe the effects of MISO on the activity of MEL in vivo at the molecular level. Using the alkaline elution technique devised by Kohn (Kohn, 1979; Kohn et al., 1976) , adapted for use in vivo with a microfluorimetric DNA assay (Cesarone et al., 1979) , it has been possible to quantitate the crosslinking activity of MEL in both normal tissues and in a fibrosarcoma. In particular, the questions we have addressed in this study are:
(1) Does pretreatment with MISO potentiate the cross-linking activity of a drug such as melphalan? (2) Is there a realistic therapeutic index from such drug combinations, i.e., is normal tissue toxicity (as related to the formation and removal of cross-links) significantly less enhanced than the antitumour effect? (3) Can we discriminate between the mechanisms discussed above for chemosensitization?
The Macmillah Press Ltd., 1983 Materials and methods Mice and tumours C3Hf /Kam mice between 12-16 weeks of age, from an SPF breeding colony, were used in this study. The fibrosarcoma (FSa) was originally induced in C3H mice by methylcholanthrene (Suit & Suchato, 1967) . Fourth and 5th isotransplant generations were kept in liquid nitrogen, and experiments were performed with the 7th generation. Tumours were grown from 5 x 105 cells injected into the hind legs of mice and were considered of suitable size when they reached -12 mm in diameter.
Preparation of tissue suspensions Animals were killed at various times following treatment, and the tissues under study were removed and immersed in ice-cold Pucks Saline A, PSA (8.0 g NaCl, 0.4 g KCI, 1.0 g glucose, and 0.35 g NaHCO3 per liter), containing 5 mM EDTA.
Necrotic and haemorrhagic tissue was separated from the viable tumour tissue and discarded. The remaining tissue was finely minced with ophthalmic scissors and syringed 6 x with 8 ml of PSA via a 15-ga. needle, then filtered through stainless steel mesh (200 wires in-1) or several layers of cotton gauze. The tumour suspension was washed twice by sedimentation at 2000 rpm for Omin in a refrigerated Beckman TJ-6 centrifuge and resuspended in fresh PSA. Cell integrity was routinely 95% as determined by trypan blue exclusion and phase contrast microscopy, and the yield of viable cells was _108 g-1 of excised tumour.
Spleen cells were obtained by cutting the spleen capsule and teasing out the cells with curved ophthalmic scissors. The cells were suspended in 10ml of PSA by vigorous pipetting, and washed twice by centrifugation and resuspension as above.
Gut suspensions were prepared by removing the first 10cm of the small intestine below the stomach. Undigested material in the lumen was removed by flushing with cold PSA via a 15-ga. needle. The gut was then cut open along its length and the mucosal layer was gently separated by scraping with a glass slide in a petri dish. The cells were suspended in PSA by very gentle pipetting and filtered through cotton gauze.
For most tissues, the number of cells could be counted with a haemacytometer. Because of the difficulty in preparing single-cell gut suspensions without damaging the cells, 1.Oml of the suspension was used for alkaline elution analysis.
Alkaline solution
The alkaline elution technique applied to in vitro systems has been described in detail (Kohn, 1979; Kohn et al., 1976 For each experiment, a blank column with filter, identical to the alkaline elutions described above but with no cells added, was run to correct for background fluorescence (see following section).
Fluorimetric assay of DNA The relative DNA concentration in each fraction was determined using the fluorescent dye Hoechst 33258 (Cesarone et al., 1979) . A 1-ml aliquot was withdrawn from each fraction, including the filter and wash solutions, and transferred to a 13 x 100mm glass culture tube. Each sample was neutralized with 0.4ml of 0.2M KH2PO4, and the volume adjusted to 2 ml with 0.6 ml of distilled water. Finally, 1 ml of Hoechst dye (1.5 x 10-6 M) in standard saline citrate was added and the tubes were vortexed. The fluorescence was determined using an Amino SPF-125 spectrofluorometer with the excitation wavelength set at ca. 350nm and the emission at ca. 460nm (the actual wavelengths were adjusted to give the maximum signal for a sample of high DNA concentration). This same procedure was performed on the blank (cell-free) experiment, and the background so determined was subtracted from the emission of each fraction in the actual elution experiment to give the corrected fluorescence intensity. The "total fluorescence" of each fraction is defined as the product of the corrected fluorescence intensity and the volume of that fraction.
Calculation of cross-linkingfactors
Cross-link factors (CLF) were estimated as follows. After preparation from the tissues, the aerated single-cell suspensions were irradiated on ice with a dose of 5Gy of X-rays from a General Electric Maximar 250 KVP X-ray machine (dose rate, 3.53 Gy min-'). This treatment introduces a uniform amount of single-strand breaks into the DNA, which is consequently eluted from the filter at a rate faster than that for the non-irradiated control (see Figure 1 ). The cells were held on ice following irradiation to prevent repair of the strand breaks. The presence of DNA cross-links results in a decrease in the rate of elution of the DNA relative to a 5-Gy irradiated control tissue with no drug treatment (e.g. see the curves shown in Figure 1 for MEL or MEL + MISO treated samples with the standard 5-Gy dose). The CLF at a particular eluted volume v is determined from: (v) logf. (v) ffo (v) where f0 (v) , f5 (v) and f,(r) are respectively the fraction of DNA remaining on the filter for the nonirradiated control, the 5-Gy control, and the 5-Gy drug-treated sample at volume v; thus a CLF of 1.0 is indicative of no cross-link formation. Unless otherwise stated, data are the average of > 3 separate experiments, and the s.e. is displayed with the mean value.
Glutathione assay Tissue concentrations of reduced glutathione were estimated by a GSH-specific fluorometric assay (Hissin & Hilf, 1976) . Results obtained with this assay were identical to those using Ellman's reagent (see Wang et al., 1980 , for details of this procedure).
Drugs and dyes Misonidazole (MISO, Hoffman-La Roche Inc.) was dissolved in saline at 45°C with periodic agitation for 10-15 min prior to use.
Melphalan (1-phenylalanine mustard, MEL) NSC no. 88806, Lot 8A-0061, was obtained from the National Cancer Institute (NCI). MEL (5mg) was dissolved in 20 ml of 0.85% saline and vortexed extensively for 10-15 min before use.
Cis-dichlorodiammineplatinum (II) (cis-platinum, cis-DDP) NSC no. 119875, Lot no. 37-3 was obtained from the NCI. It was dissolved in salinemannitol (1% mannitol containing 1 g I of NaCl).
Hoechst 33258 (Aldrich), o-phthalicdicarboxaldehyde, OPT (Aldrich), reduced glutathione, GSH (Calbiochem), and diethyl maleate, DEM (Aldrich) were used as received. DEM was dissolved in sesame oil. Unless otherwise stated, all drugs were injected i.p.
Results
Typical alkaline elution profiles from an experiment in which MISO (1 mg g 1) was injected 30 min prior to MEL (5mgkg-1, 12h exposure) are shown in Figure la and lb for FSa and spleen, respectively.
Volume eluted (ml) Figure 1 Typical alkaline elution profiles for (a) tumour and (b) spleen showing non-irradiated (V) and 5-Gy irradiated (A) controls (no drug treatment), and tissues from mice treated with MEL (5mgkg-', i.p., 12h) in vivo, with (0) or without (0) pretreatment with MISO (1 mgkg-1, i.p., 0.5h), and subsequently exposed to 5 Gy of X-rays. Irradiation of the tissue suspensions was performed in vitro on ice just prior to analysis by alkaline elution.
B
The slower rate of elution for the combined drug schedule relative to MEL alone is indicative of a greater degree of cross-linking in the MISOpretreated animal for each tissue studied. MISO alone for periods from 0.5-6 h produced no detectable strand-breaks or cross-links in any tissue; elution profiles for both 0-Gy and 5-Gy doses (irradiated in vitro) were essentially identical to those from respective untreated control animals.
In order to establish cross-linking levels in tissues treated with MEL alone in vivo, the kinetics of the formation and repair of cross-links were analyzed in FSa, gut and spleen. In both tumour (Figure 2 ), spleen (Figure 3) , and gut ( Figure 4 ) the level of cross-linking increased gradually, reaching a maximum between 6-16 h and then decreasing thereafter, presumably due to repair and/or cell turnover. The relative amount of cross-linking in each tissue was assessed by integration of the curves shown in Figures 2-4 between 0-24h. These data are included in Table 1 , values being normalised to the lowest observed degree of cross-linking (i.e. gut). FSa exhibited a greater degree of cross-linking at each time point with MEL treatment alone than did the normal tissues. Thus there appears to be an intrinsic difference in cross-link formation between tumour and normal tissues treated with MEL alone.
The kinetics of the formation and disappearance of the cross-links induced by a single dose of MEL (5mgkg-1) after a 30min pretreatment with MISO (1mgg-') are also shown in Figures 2-4 for FSa, spleen, and gut, respectively. At all times between 6-72 h, more cross-linking was detected in all tissues from the MISO-treated animal. For gut (Figure 4 ), data at <6h were subject to large variations, but at all times >6 h an enhancement by MISO was observed. The overall enhancement was calculated from the ratio of the areas under the graph of CLF versus time between 0-24 h in the presence and absence of MISO. This time period was chosen in order to minimize errors due to cell turnover, and also since cross-link repair processes in vitro appear to be completed by this time (Taylor et al., 1982b; Meyn et al., 1982) . The calculated enhancement factors (Table I) (Table  II) , the DNA from the combined drug-treated animals eluting at essentially the same rate as from those treated with cis-DDP alone.
Since it was anticipated that intracellular sulphydryl-containing compounds may be involved in the action of MISO at the molecular level, we investigated the possible involvement of GSH depletion in MISO chemosensitization. The nucleophilic GSH is involved in the elimination of toxic electrophilic species such as the nitrogen mustards (e.g., see Millar, 1982) . Also, Clement et (1980) , have implicated the possible involvement of free-radical intermediates in the MISO potentiation of MEL and other drugs, and GSH is known to act as an intracellular free-radical scavenger. The effect of MISO was compared with that of diethyl maleate, DEM, a reagent that has been shown to selectively deplete GSH levels both in vitro and in vivo (Bump et al., 1982) . The Figure 5 . Results for liver are included as controls since DEM has been shown to cause marked depletion of hepatic GSH in mice (e.g., see Gurtoo et al., 1981) and in rats (Younes & Siegers, 1981) . DEM (700mgkg-1) resulted in large 1 h) and somewhat less in spleen (to 64% at 1 h) and tumour (to 68% at 2 h). MISO (1 mg g-1) also depleted GSH in liver (to 62% of a control at 1 h) and tumour (to 75% at 2 h), but did not affect spleen up to 6 h post-injection. When administered 30 min prior to MEL (5mgkg-1), DEM (700mgkg-1) caused a pronounced enhancement of cross-linking in both spleen and tumour at 6 h post-injection (Table III) . Millar, 1982, and McNally, 1982) . As mentioned earlier, the mechanism of this chemosensitization effect is still very unclear, although there is general agreement that the tumour response is somewhat more pronounced than that of normal tissues.
If we assume that MEL-induced cross-links are responsible for its cytotoxicity, the results shown here suggest that it is possible to account in full for the increased cytotoxicity and differential effects of MISO on tumour and normal tissue solely on the basis of the enhanced cross-linking observed without considering any selective killing of hypoxic cells. The enhancement in tumour (by a factor of 2.0 Table I ) and in normal tissues in the tumourbearing animal (by a factor of 1.4-1.5, Table I ) is comparable to the enhancement observed for tumour response and normal tissue toxicities in other studies (see Fowler, 1982) . The greater enhancement of FSa, combined with the observation (Table I ) that the tumour is intrinsically more sensitive than two normal tissues to cross-linking by MEL, confirms that a realistic therapeutic index may be achieved using combined drug treatments, especially once the scheduling and dosage are optimized. The scheduling of the drug treatments in this work was selected on the basis of a previously published study (Rose et al., 1980) , so that comparisons with survival and tumour regrowth data could be made.
The kinetics of MEL-induced cross-link formation and disappearance (Figure 2 and Figure 3) , with the CLF increasing with time up to a maximum at -12 h and then slowly decreasing, are similar to results observed with mouse leukaemia L1210 cells (Ross et al., 1978) and with CHO cells (Taylor et al., 1982b) in vitro. This suggests that the mechanism of MEL induced cross-link formation in vivo and in vitro are essentially the same, possibly reflecting a slow second step in the formation of the actual cross-link subsequent to the production of a monofunctionally bound MEL species. The high level of residual cross-links at times >24h that we observed here for each tissue was also found in vitro with the L1210 cell line (Ross et al., 1978) , whereas with cultured CHO cells most of the MEL cross-links were repaired by 24 h (Taylor et al., 1982b) .
The mechanism of chemosensitization and the enhancement of cross-linking drugs by MISO remains to be elucidated. However, if the cytotoxicity of MEL is a reflection of the DNA cross-linking it produces, then it seems reasonable that repair of PLD in MEL treated tissues may be associated with the repair of these lesions or their monoadduct precursors; MISO pretreatment could therefore result in enhanced cross-linking if it inhibited such repair processes. MISO has been reported to inhibit the repair of MEL-and cyclophosphamide-induced PLD in several tumour lines (Law et al., 1981; Martin et al., 1981) , while a tumour in which no repair of PLD could be observed showed a markedly lower degree of MISO-chemosensitization (Martin et al., 1981) . Siemann & Mulcahy (1982) have shown that for a series of nitrosoureas the MISO enhancement ratios correlate with the extent of PLD repair inhibition. However, in other tumours in which there was no apparent repair of PLD, MISO has still been observed to enhance the effect of MEL (Rose et al., 1980) and cyclophosphamide (Siemann & Mulcahy, 1982) . Similarly, in vitro studies have shown that enhanced MEL cytotoxicity is not related to inhibition of PLD repair (Horsman et al., 1982) . Because of the low levels of cross-linking observed here with MEL when given i.p., and also the large fraction of residual cross-links, it is somewhat difficult to assess the extent of cross-link repair, except in the case of the tumour (Figure 2) where some repair is evident between 12-20 h and this does not appear to be altered by MISO pretreatment. Taylor et al., (1982b) have shown that MISO enhances MEL-induced cross-link formation by a factor of -4 in vitro, but that these cross-links are essentially all removed by 24h with or without MISO pretreatment, again there being no evidence for inhibition of cross-link repair. In preliminary in vivo experiments where MEL was administered iv, much greater cross-linking factors were observed (CLF >3 for FSa) and most of these cross-links had been removed by 24 h in both FSa and in normal tissues (Jenkins & Meyn, unpublished data) . Experiments are in progress to establish whether MISO inhibits these repair processes.
The observation that MISO pretreatment results in increased levels of MEL-induced cross-links at each time point, without apparently altering the kinetics of their formation of their removal ( Figures  2-4) , is best explained by one of two alternative models:
1. The more obvious explanation is that MISO pretreatment could increase the initial amount of MEL bound to DNA prior to the formation of cross-links, via mechanisms involving alterations in drug pharmacokinetics or enhanced intracellular uptake. The monofunctionally bound MEL species referred to above would then be subsequently expressed as cross-links in the time period up to 12h post-injection. Any mechanism that would increase the extent of MEL binding at early times would suitably account for both the enhancement and the observed kinetics. Pharmacokinetic alterations could result in more effective delivery of MEL, producing a higher initial concentration of such DNA/MEL species discussed above. In support of this mechanism, MISO has been reported to increase both the serum retention time and peak serum level of MEL in mice (Clutterbuck et al., 1982 Preincubation with MISO did not enhance the cross-linking activity of cis-DDP (Table II) . Although MISO has been found to enhance cis-DDP cytotoxicity in vitro (Stratford et al., 1980; Roizin-Towle & Hall, 1981) , there is no apparent in vivo sensitization (Rose et al., 1980; Clement et al., 1980; Stephens et al., 1981) . As noted previously (Clement et al., 1980) , this may be due to the fact that cis-DDP exerts its cross-linking effect via a coordination mechanism that does not involve freeradical intermediates (Rosenberg, 1979) .
Since MISO is known to deplete intracellular levels of GSH in hypoxic cells (Varnes et al., 1980; Taylor et al., 1982a ), we also investigated the possible involvement of glutathione in chemosensitization. Both DEM and MISO did cause a significant alteration of GSH levels ( Figure  5 ), but this was tissue specific and possibly related to the requirement of hypoxia for MISO but not for DEM to deplete GSH in vitro (Varnes et al., 1980) . Although the enhancement of MEL cross-linking by DEM in both spleen and tumour (by a factor of 2.0 and 1.8, respectively, see Table III ) may be related to GSH depletion, the lack of GSH depletion by MISO in spleen despite the observed enhancement of MEL by MISO (by a factor of 1.5) in this tissue suggests that, while GSH depletion may play a part in chemosensitization, it is unlikely to account for the whole effect. Although MISO has been found to deplete GSH in hypoxic cells, depletion could only account for part (15-20%) of the increased cytotoxicity of MEL (Taylor et al., 1982a., b) . The lack of GSH depletion by MISO in spleen is probably indicative of a relative absence of hypoxic cells therein.
In summary, we have shown that pretreatment with misonidazole increases drug-induced crosslinking in tissues in vivo after subsequent exposure to alkylating agents such as melphalan. However, because of the relatively slow rates of cross-link formation and removal with this drug, it is difficult to discriminate between several possible mechanisms for this effect. Studies using drugs with which cross-link formation is expressed almost immediately in vitro, such as mitomycin C (Meyn et al., 1982) or nitrogen mustard (Ross et al., 1978) are currently being investigated so that events occurring at much earlier times may be observed in vivo.
